<img src="https://ml.globenewswire.com/Resource/Download/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Milestone Pharmaceuticals Logo.png" alt="Milestone Pharmaceuticals Inc."/>MONTREAL&#160;and&#160;CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the <a href="https://www.globenewswire.com/Tracker?data=gSbIyFbCYzurPpwF0pYKEXH8C3FF68geTqh3n79nCYdL1qPKKpEO3jnk_RNm5uSejTd8tVgJQ8_1Xh5k6jeHvirdHeTvpY_aviIzjothhmdkxTB5GZ45QF5-mQNuvmxGiPlfRD-j-vUL4Lcj-U3s4J3qql6WCXWK4u5_4vkGoMoEhk5S2h9w09KZXZoPWSAC_bRxcvhgj48aqwRJiofV7A==" rel="nofollow" target="_blank" title="H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ">H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ</a> to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both <a href="https://www.globenewswire.com/Tracker?data=t7UzMAuF77Y1gL0FvKbH8y1r9_o-v1ep7Vgk-5VFXiqtnMKUXC3iMMFucRGJCTF0lzVQVQK_q35iOSBAbK73Gqh4gj7afn1BAYSaUZCfEXnY-KprI_1zNbsY58MfiT2vgSnux4xnPA8GonCViT12kQ==" rel="nofollow" target="_blank" title="live">live</a> and replay for approximately 90-days following the presentation on the News &amp; Events section of Milestone's website <a href="https://www.globenewswire.com/Tracker?data=c4QJDsochv-hcbIsFEhKxA1ksImz-V4gv9iXTY29-FKg2jX5cSKUAfgFyOwV7wNzI6sezy9hGVr0GcK6ZNHS17RtmCQEGwYVnGywH1VDoHs=" rel="nofollow" target="_blank" title="www.milestonepharma.com">www.milestonepharma.com</a>. If you are interested in meeting with the Milestone team during the conference, please contact your H.C. Wainwright representative. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR. Contact: Investor Relations Kevin Gardner, <a href="https://www.globenewswire.com/Tracker?data=8p1uKUZ4e2CyGsEHpcJCIwahb9SomGyaUMJO_AW8oLPopwSIqkRmQYPVlPPZAEAH2TATn5JK8bZqoqueFZYmTpg4rw2xFsBKFVUePOwWdngVlBQh_cs-Emh3syk7O06z" rel="nofollow" target="_blank" title="kgardner@lifesciadvisors.com">kgardner@lifesciadvisors.com</a> Media Relations  Rebecca Novak, <a href="https://www.globenewswire.com/Tracker?data=jQEU5hOowkP9WdbUkAXpRUMW4cBT_2AZucZ4XA2pIniOVN7JThf1Tfi7IWYcNSWyHuQnjnzXiYyVLCXlLQAb2hnaE2kJfZlAOViur45NJQwXMpTbG5nPWWxD_duHnRJmKkPTaaPcE5eKmFAqvKuj04iOs2aEZyK4O6F_5yj-T3-8xjM_EYHNRrLYXpQPLLJDiQVqjjfZb62VcqYnRaXH7R0VnCEVXH3EYZsNc1ruxMgwVJXs1DLOIZ6QJ3_oVawMC5KYecu6qsjMXf_rZyljFU2PhOa5zkI0LzEXhe09D3iBeMWMS8aZytoxFbNSXZ7Mkm0f-onlz1BI5_l8_8Aha9aOx8Z9dYC60ZmrAFh1QkLOxwq3weqGTRFPeLS1rsIOgc3hP3wBmtHozrBWRfNI0JRjiBUoag1fGIyXMWxiKx3oLYUyck4vybjvmfMvTQM5ivHYobJg2enboaoEfOELxf0jc_qFehdkWfX9DQg2PMcljP8SWoYRv0kuHPtXJ4VwLbZRiEEf-rscAdgEw8cxpUg1_GGmyZvX96NxNwbE9GQ=" rel="nofollow" target="_blank" title="rnovak@milestonepharma.com">rnovak@milestonepharma.com</a> <img alt="" src='https://ml.globenewswire.com/media/OWQ2OTM1YTItZjc2OC00NDQ0LWJmZTEtYTMzMDI4ZTczYmRjLTUwMDEyMTAzNi0yMDI2LTA1LTE0LWVu/tiny/Milestone-Pharmaceuticals-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn